Trial Profile
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Indocyanine green
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Aug 2011 Planned end date changed from Feb 2008 to Jan 2012 as reported by ClinicalTrials.gov.
- 08 Aug 2011 Planned end date changed from Feb 2008 to Jan 2012 as reported by ClinicalTrials.gov.
- 10 Jun 2008 New trial record.